ID   CODA_ECOLI              Reviewed;         427 AA.
AC   P25524; Q2MC87;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   15-FEB-2017, entry version 139.
DE   RecName: Full=Cytosine deaminase {ECO:0000303|PubMed:1640834, ECO:0000303|PubMed:8226944};
DE            Short=CD {ECO:0000303|PubMed:15381761};
DE            Short=CDA {ECO:0000303|PubMed:21545144};
DE            Short=CDase {ECO:0000303|PubMed:8226944};
DE            EC=3.5.4.1 {ECO:0000269|PubMed:15381761, ECO:0000269|PubMed:21545144, ECO:0000269|PubMed:21604715, ECO:0000269|PubMed:8226944};
DE   AltName: Full=Cytosine aminohydrolase;
DE   AltName: Full=Isoguanine deaminase {ECO:0000303|PubMed:21604715};
DE            EC=3.5.4.- {ECO:0000269|PubMed:21604715};
GN   Name=codA; OrderedLocusNames=b0337, JW0328;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-20.
RC   STRAIN=CSH01;
RX   PubMed=1640834; DOI=10.1111/j.1365-2958.1992.tb00854.x;
RA   Danielsen S., Kilstrup M., Barilla K., Jochimsen B., Neuhard J.;
RT   "Characterization of the Escherichia coli codBA operon encoding
RT   cytosine permease and cytosine deaminase.";
RL   Mol. Microbiol. 6:1335-1344(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8450832;
RA   Austin E.A., Huber B.E.;
RT   "A first step in the development of gene therapy for colorectal
RT   carcinoma: cloning, sequencing, and expression of Escherichia coli
RT   cytosine deaminase.";
RL   Mol. Pharmacol. 43:380-387(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RA   Chung E., Allen E., Araujo R., Aparicio A.M., Davis K., Duncan M.,
RA   Federspiel N., Hyman R., Kalman S., Komp C., Kurdi O., Lew H., Lin D.,
RA   Namath A., Oefner P., Roberts D., Schramm S., Davis R.W.;
RT   "Sequence of minutes 4-25 of Escherichia coli.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND ENZYME REGULATION.
RX   PubMed=8226944;
RA   Porter D.J., Austin E.A.;
RT   "Cytosine deaminase. The roles of divalent metal ions in catalysis.";
RL   J. Biol. Chem. 268:24005-24011(1993).
RN   [7]
RP   SUBUNIT.
RX   PubMed=11679731; DOI=10.1107/S0907444901011064;
RA   Ireton G.C., Black M.E., Stoddard B.L.;
RT   "Crystallization and preliminary X-ray analysis of bacterial cytosine
RT   deaminase.";
RL   Acta Crystallogr. D 57:1643-1645(2001).
RN   [8]
RP   REVIEW, AND BIOTECHNOLOGY.
RX   PubMed=25338741; DOI=10.1208/s12248-014-9675-7;
RA   Zhang J., Kale V., Chen M.;
RT   "Gene-directed enzyme prodrug therapy.";
RL   AAPS J. 17:102-110(2015).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF APOENZYME AND IN COMPLEX
RP   WITH A MECHANISM-BASED INHIBITOR AND IRON, REACTION MECHANISM, AND
RP   ACTIVE SITE.
RX   PubMed=11812140; DOI=10.1006/jmbi.2001.5277;
RA   Ireton G.C., McDermott G., Black M.E., Stoddard B.L.;
RT   "The structure of Escherichia coli cytosine deaminase.";
RL   J. Mol. Biol. 315:687-697(2002).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.12 ANGSTROMS) OF MUTANTS GLY-314; ALA-314 AND
RP   SER-315 UNCOMPLEXED AND IN COMPLEX WITH
RP   (4S)-5-FLUORO-4-HYDROXY-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE AND IRON,
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   MUTAGENESIS OF ASP-314, AND BIOTECHNOLOGY.
RX   PubMed=15381761; DOI=10.1093/protein/gzh074;
RA   Mahan S.D., Ireton G.C., Knoeber C., Stoddard B.L., Black M.E.;
RT   "Random mutagenesis and selection of Escherichia coli cytosine
RT   deaminase for cancer gene therapy.";
RL   Protein Eng. Des. Sel. 17:625-633(2004).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 5-427 OF MUTANT
RP   ALA-153/CYS-317/GLY-318 IN COMPLEX WITH IRON, AND BIOTECHNOLOGY.
RX   PubMed=19487291; DOI=10.1158/0008-5472.CAN-09-0615;
RA   Fuchita M., Ardiani A., Zhao L., Serve K., Stoddard B.L., Black M.E.;
RT   "Bacterial cytosine deaminase mutants created by molecular engineering
RT   show improved 5-fluorocytosine-mediated cell killing in vitro and in
RT   vivo.";
RL   Cancer Res. 69:4791-4799(2009).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) IN COMPLEX WITH
RP   PHOSPHONOCYTOSINE INHIBITOR AND ZINC, FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME
RP   REGULATION, MUTAGENESIS OF GLN-157; GLU-218; HIS-247 AND ASP-314,
RP   ACTIVE SITES, AND REACTION MECHANISM.
RC   STRAIN=K12;
RX   PubMed=21545144; DOI=10.1021/bi200483k;
RA   Hall R.S., Fedorov A.A., Xu C., Fedorov E.V., Almo S.C., Raushel F.M.;
RT   "Three-dimensional structure and catalytic mechanism of cytosine
RT   deaminase.";
RL   Biochemistry 50:5077-5085(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.26 ANGSTROMS) IN COMPLEX WITH ISOGUANINE AND
RP   ZINC, IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, CATALYTIC
RP   ACTIVITY, IDENTIFICATION OF ISOGUANINE AS SUBSTRATE,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND DISRUPTION PHENOTYPE.
RX   PubMed=21604715; DOI=10.1021/bi200680y;
RA   Hitchcock D.S., Fedorov A.A., Fedorov E.V., Dangott L.J., Almo S.C.,
RA   Raushel F.M.;
RT   "Rescue of the orphan enzyme isoguanine deaminase.";
RL   Biochemistry 50:5555-5557(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH ZINC.
RA   Fedorov A.A., Fedorov E.V., Kamat S., Hitchcock D., Raushel F.M.,
RA   Almo S.C.;
RT   "Crystal structure of cytosine deaminase from Escherichia coli
RT   complexed with two zinc atoms in the active site.";
RL   Submitted (MAR-2011) to the PDB data bank.
CC   -!- FUNCTION: Catalyzes the hydrolytic deamination of cytosine to
CC       uracil. Is involved in the pyrimidine salvage pathway, which
CC       allows the cell to utilize cytosine for pyrimidine nucleotide
CC       synthesis. Is also able to catalyze deamination of isoguanine, a
CC       mutagenic oxidation product of adenine in DNA, and of isocytosine.
CC       To a lesser extent, also catalyzes the conversion of 5-
CC       fluorocytosine (5FC) to 5-fluorouracil (5FU); this activity allows
CC       the formation of a cytotoxic chemotherapeutic agent from a non-
CC       cytotoxic precursor. {ECO:0000269|PubMed:15381761,
CC       ECO:0000269|PubMed:21545144, ECO:0000269|PubMed:21604715,
CC       ECO:0000269|PubMed:8226944}.
CC   -!- CATALYTIC ACTIVITY: Cytosine + H(2)O = uracil + NH(3).
CC       {ECO:0000269|PubMed:15381761, ECO:0000269|PubMed:21545144,
CC       ECO:0000269|PubMed:21604715, ECO:0000269|PubMed:8226944}.
CC   -!- CATALYTIC ACTIVITY: Isoguanine + H(2)O = xanthine + NH(3).
CC       {ECO:0000269|PubMed:21604715}.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:21545144,
CC         ECO:0000269|PubMed:8226944};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:8226944};
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:21545144,
CC         ECO:0000269|PubMed:8226944};
CC       Note=The purified enzyme contains a mixture of Fe(2+) and Zn(2+)
CC       bound in the active site, and a single equivalent of metal is
CC       required for full catalytic activity. After removal of the metal,
CC       the reconstitution of the enzyme with Fe(2+) gives the highest
CC       activity, followed by Mn(2+), and, to a much lesser extent, Co(2+)
CC       and Zn(2+). {ECO:0000269|PubMed:21545144,
CC       ECO:0000269|PubMed:8226944};
CC   -!- ENZYME REGULATION: Fe(2+)-CDase is rapidly inactivated by
CC       H(2)O(2), whereas Mn(2+)-CDase, Co(2+)-CDase, and Zn(2+)-CDase are
CC       not inactivated by H(2)O(2). CDase is also inhibited by excess
CC       divalent cations (PubMed:8226944). Phosphonocytosine, a mimic of
CC       the tetrahedral reaction intermediate, inhibits the deamination of
CC       cytosine with a Ki of 52 nM (PubMed:21545144).
CC       {ECO:0000269|PubMed:21545144, ECO:0000269|PubMed:8226944}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.22 mM for cytosine {ECO:0000269|PubMed:8226944};
CC         KM=0.2 mM for cytosine {ECO:0000269|PubMed:15381761};
CC         KM=3.3 mM for 5-fluorocytosine {ECO:0000269|PubMed:15381761};
CC         KM=0.97 mM for cytosine {ECO:0000269|PubMed:21545144};
CC         KM=0.46 mM for isocytosine {ECO:0000269|PubMed:21545144};
CC         KM=25 mM for creatinine {ECO:0000269|PubMed:21545144};
CC         KM=4.1 mM for 3-oxauracil {ECO:0000269|PubMed:21545144};
CC         KM=72 uM for isoguanine {ECO:0000269|PubMed:21604715};
CC         KM=302 uM for cytosine {ECO:0000269|PubMed:21604715};
CC         Note=kcat is 185 sec(-1) for the deamination of cytosine using
CC         Fe(2+) as cofactor, kcat is 92 sec(-1) using Mn(2+) as cofactor,
CC         kcat is 52 sec(-1) using Co(2+) as cofactor, and kcat is 32
CC         sec(-1) using Zn(2+) as cofactor (PubMed:8226944). kcat is 165
CC         sec(-1) for the deamination of cytosine and 75.6 sec(-1) for the
CC         deamination of 5-fluorocytosine (PubMed:15381761). kcat is 132
CC         sec(-1) for the deamination of cytosine, 5.1 sec(-1) for the
CC         deamination of isocytosine, 5.6 sec(-1) for the deamination of
CC         creatinine and 2.3 sec(-1) for the hydrolysis of 3-oxauracil
CC         (PubMed:21545144). kcat is 45 sec(-1) for the deamination of
CC         cytosine and 49 sec(-1) for the deamination of isoguanine at pH
CC         7.7 (PubMed:21604715). {ECO:0000269|PubMed:15381761,
CC         ECO:0000269|PubMed:21545144, ECO:0000269|PubMed:21604715,
CC         ECO:0000269|PubMed:8226944};
CC       pH dependence:
CC         Activity is lost under pH 5 but not affected up to pH 10.
CC         {ECO:0000269|PubMed:21545144};
CC   -!- SUBUNIT: Homohexamer. {ECO:0000269|PubMed:11679731}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-559181, EBI-559181;
CC   -!- DISRUPTION PHENOTYPE: Cells lacking this gene have less than 1% of
CC       the isoguanine deaminase activity of the wild-type strain.
CC       {ECO:0000269|PubMed:21604715}.
CC   -!- BIOTECHNOLOGY: Cytosine deaminase is being explored for use as a
CC       suicide gene for cancer gene therapy. The cytosine deaminase/5-
CC       fluorouracil combined therapy has been used successfully for a
CC       variety of animal tumor models and is currently under
CC       investigation for the treatment of human cancers.
CC       {ECO:0000269|PubMed:19487291, ECO:0000303|PubMed:25338741,
CC       ECO:0000305|PubMed:15381761}.
CC   -!- SIMILARITY: Belongs to the cytosine deaminase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18061.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X63656; CAA45196.1; -; Genomic_DNA.
DR   EMBL; S56903; AAB25761.2; -; Genomic_DNA.
DR   EMBL; U73857; AAB18061.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U00096; AAC73440.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE76119.1; -; Genomic_DNA.
DR   PIR; S22662; S22662.
DR   RefSeq; NP_414871.1; NC_000913.3.
DR   RefSeq; WP_001301240.1; NZ_LN832404.1.
DR   PDB; 1K6W; X-ray; 1.75 A; A=2-427.
DR   PDB; 1K70; X-ray; 1.80 A; A=2-427.
DR   PDB; 1R9X; X-ray; 1.58 A; A=2-427.
DR   PDB; 1R9Y; X-ray; 1.57 A; A=2-427.
DR   PDB; 1R9Z; X-ray; 1.32 A; A=2-427.
DR   PDB; 1RA0; X-ray; 1.12 A; A=2-427.
DR   PDB; 1RA5; X-ray; 1.40 A; A=2-427.
DR   PDB; 1RAK; X-ray; 1.32 A; A=2-427.
DR   PDB; 3G77; X-ray; 1.80 A; A=5-427.
DR   PDB; 3O7U; X-ray; 1.71 A; A=1-427.
DR   PDB; 3R0D; X-ray; 1.50 A; A=1-427.
DR   PDB; 3RN6; X-ray; 2.26 A; A=1-427.
DR   PDBsum; 1K6W; -.
DR   PDBsum; 1K70; -.
DR   PDBsum; 1R9X; -.
DR   PDBsum; 1R9Y; -.
DR   PDBsum; 1R9Z; -.
DR   PDBsum; 1RA0; -.
DR   PDBsum; 1RA5; -.
DR   PDBsum; 1RAK; -.
DR   PDBsum; 3G77; -.
DR   PDBsum; 3O7U; -.
DR   PDBsum; 3R0D; -.
DR   PDBsum; 3RN6; -.
DR   ProteinModelPortal; P25524; -.
DR   SMR; P25524; -.
DR   BioGrid; 4259813; 4.
DR   DIP; DIP-9306N; -.
DR   IntAct; P25524; 6.
DR   MINT; MINT-1307853; -.
DR   STRING; 511145.b0337; -.
DR   PaxDb; P25524; -.
DR   PRIDE; P25524; -.
DR   EnsemblBacteria; AAC73440; AAC73440; b0337.
DR   EnsemblBacteria; BAE76119; BAE76119; BAE76119.
DR   GeneID; 944996; -.
DR   KEGG; ecj:JW0328; -.
DR   KEGG; eco:b0337; -.
DR   PATRIC; 32115805; VBIEscCol129921_0344.
DR   EchoBASE; EB1302; -.
DR   EcoGene; EG11326; codA.
DR   eggNOG; ENOG4105DZC; Bacteria.
DR   eggNOG; COG0402; LUCA.
DR   HOGENOM; HOG000184778; -.
DR   InParanoid; P25524; -.
DR   KO; K01485; -.
DR   OMA; AFPQDGY; -.
DR   PhylomeDB; P25524; -.
DR   BioCyc; EcoCyc:CYTDEAM-MONOMER; -.
DR   BioCyc; MetaCyc:CYTDEAM-MONOMER; -.
DR   BRENDA; 3.5.4.1; 2026.
DR   EvolutionaryTrace; P25524; -.
DR   PRO; PR:P25524; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0102480; F:5-fluorocytosine deaminase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004131; F:cytosine deaminase activity; IDA:EcoCyc.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:EcoCyc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0035888; F:isoguanine deaminase activity; IDA:EcoCyc.
DR   GO; GO:0008270; F:zinc ion binding; IDA:EcoCyc.
DR   GO; GO:0006209; P:cytosine catabolic process; IMP:EcoCyc.
DR   Gene3D; 2.30.40.10; -; 1.
DR   InterPro; IPR013108; Amidohydro_3.
DR   InterPro; IPR011059; Metal-dep_hydrolase_composite.
DR   InterPro; IPR032466; Metal_Hydrolase.
DR   Pfam; PF07969; Amidohydro_3; 1.
DR   SUPFAM; SSF51338; SSF51338; 1.
DR   SUPFAM; SSF51556; SSF51556; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytosine metabolism;
KW   Direct protein sequencing; Hydrolase; Iron; Metal-binding;
KW   Reference proteome; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:1640834}.
FT   CHAIN         2    427       Cytosine deaminase.
FT                                /FTId=PRO_0000090002.
FT   ACT_SITE    218    218       Proton donor.
FT                                {ECO:0000305|PubMed:11812140,
FT                                ECO:0000305|PubMed:21545144,
FT                                ECO:0000305|PubMed:21604715}.
FT   METAL        62     62       Iron or zinc; catalytic.
FT                                {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:19487291,
FT                                ECO:0000269|PubMed:21545144,
FT                                ECO:0000269|PubMed:21604715,
FT                                ECO:0000269|Ref.14}.
FT   METAL        64     64       Iron or zinc; catalytic.
FT                                {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:19487291,
FT                                ECO:0000269|PubMed:21545144,
FT                                ECO:0000269|PubMed:21604715,
FT                                ECO:0000269|Ref.14}.
FT   METAL       215    215       Iron or zinc; catalytic.
FT                                {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:19487291,
FT                                ECO:0000269|PubMed:21545144,
FT                                ECO:0000269|PubMed:21604715,
FT                                ECO:0000269|Ref.14}.
FT   METAL       314    314       Iron or zinc; catalytic.
FT                                {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:19487291,
FT                                ECO:0000269|PubMed:21545144,
FT                                ECO:0000269|PubMed:21604715,
FT                                ECO:0000269|Ref.14}.
FT   BINDING     157    157       Substrate. {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:21545144,
FT                                ECO:0000269|PubMed:21604715}.
FT   BINDING     320    320       Substrate. {ECO:0000269|PubMed:11812140,
FT                                ECO:0000269|PubMed:15381761,
FT                                ECO:0000269|PubMed:21545144}.
FT   SITE        247    247       Activates the nucleophilic water.
FT                                {ECO:0000305|PubMed:21545144,
FT                                ECO:0000305|PubMed:21604715}.
FT   VARIANT      13     13       R -> W (in strain: SO5076).
FT   MUTAGEN     157    157       Q->A,N: Less than 0.01% of wild-type
FT                                enzymatic activity.
FT                                {ECO:0000269|PubMed:21545144}.
FT   MUTAGEN     218    218       E->A,Q: Less than 0.01% of wild-type
FT                                enzymatic activity.
FT                                {ECO:0000269|PubMed:21545144}.
FT   MUTAGEN     247    247       H->A,N: Less than 0.01% of wild-type
FT                                enzymatic activity.
FT                                {ECO:0000269|PubMed:21545144}.
FT   MUTAGEN     247    247       H->Q: 200-fold decrease in catalytic
FT                                efficiency.
FT                                {ECO:0000269|PubMed:21545144}.
FT   MUTAGEN     314    314       D->A: 17-fold decrease in catalytic
FT                                efficiency with cytosine as substrate and
FT                                2-fold increase in that with 5FC as
FT                                substrate. Shows increased sensitivity to
FT                                5FC. {ECO:0000269|PubMed:15381761}.
FT   MUTAGEN     314    314       D->A: Less than 0.01% of wild-type
FT                                enzymatic activity.
FT                                {ECO:0000269|PubMed:21545144}.
FT   MUTAGEN     314    314       D->G,S: Still active towards cytosine.
FT                                Shows increased sensitivity to 5FC.
FT                                {ECO:0000269|PubMed:15381761}.
FT   MUTAGEN     314    314       D->K,R,H: Loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15381761}.
FT   MUTAGEN     314    314       D->N: 35000-fold decrease in catalytic
FT                                efficiency.
FT                                {ECO:0000269|PubMed:21545144}.
FT   STRAND        8     13       {ECO:0000244|PDB:1RA0}.
FT   STRAND       19     26       {ECO:0000244|PDB:1RA0}.
FT   STRAND       29     38       {ECO:0000244|PDB:1RA0}.
FT   STRAND       46     48       {ECO:0000244|PDB:1RA0}.
FT   STRAND       53     56       {ECO:0000244|PDB:1RA0}.
FT   STRAND       58     63       {ECO:0000244|PDB:1RA0}.
FT   TURN         65     69       {ECO:0000244|PDB:1RA0}.
FT   STRAND       73     75       {ECO:0000244|PDB:1RA0}.
FT   HELIX        82     93       {ECO:0000244|PDB:1RA0}.
FT   HELIX        98    114       {ECO:0000244|PDB:1RA0}.
FT   STRAND      117    125       {ECO:0000244|PDB:1RA0}.
FT   HELIX       132    144       {ECO:0000244|PDB:1RA0}.
FT   TURN        145    147       {ECO:0000244|PDB:1RA0}.
FT   STRAND      149    155       {ECO:0000244|PDB:1RA0}.
FT   STRAND      160    163       {ECO:0000244|PDB:1RA0}.
FT   HELIX       166    175       {ECO:0000244|PDB:1RA0}.
FT   STRAND      179    181       {ECO:0000244|PDB:1RA0}.
FT   HELIX       185    187       {ECO:0000244|PDB:1RA0}.
FT   STRAND      188    190       {ECO:0000244|PDB:1RA0}.
FT   HELIX       191    208       {ECO:0000244|PDB:1RA0}.
FT   STRAND      211    216       {ECO:0000244|PDB:1RA0}.
FT   HELIX       226    237       {ECO:0000244|PDB:1RA0}.
FT   HELIX       240    242       {ECO:0000244|PDB:1RA0}.
FT   STRAND      243    247       {ECO:0000244|PDB:1RA0}.
FT   HELIX       249    253       {ECO:0000244|PDB:1RA0}.
FT   HELIX       256    269       {ECO:0000244|PDB:1RA0}.
FT   STRAND      272    275       {ECO:0000244|PDB:1RA0}.
FT   HELIX       277    283       {ECO:0000244|PDB:1RA0}.
FT   TURN        284    287       {ECO:0000244|PDB:1RA0}.
FT   HELIX       299    304       {ECO:0000244|PDB:1RA0}.
FT   STRAND      309    311       {ECO:0000244|PDB:1RA0}.
FT   STRAND      316    318       {ECO:0000244|PDB:1RA0}.
FT   HELIX       328    338       {ECO:0000244|PDB:1RA0}.
FT   HELIX       344    348       {ECO:0000244|PDB:1RA0}.
FT   HELIX       349    354       {ECO:0000244|PDB:1RA0}.
FT   HELIX       356    361       {ECO:0000244|PDB:1RA0}.
FT   STRAND      368    370       {ECO:0000244|PDB:3R0D}.
FT   STRAND      373    375       {ECO:0000244|PDB:3RN6}.
FT   STRAND      377    384       {ECO:0000244|PDB:1RA0}.
FT   HELIX       385    391       {ECO:0000244|PDB:1RA0}.
FT   STRAND      396    400       {ECO:0000244|PDB:1RA0}.
FT   STRAND      403    407       {ECO:0000244|PDB:1RA0}.
FT   STRAND      413    423       {ECO:0000244|PDB:1RA0}.
SQ   SEQUENCE   427 AA;  47591 MW;  9F91A2C46B3B1E42 CRC64;
     MSNNALQTII NARLPGEEGL WQIHLQDGKI SAIDAQSGVM PITENSLDAE QGLVIPPFVE
     PHIHLDTTQT AGQPNWNQSG TLFEGIERWA ERKALLTHDD VKQRAWQTLK WQIANGIQHV
     RTHVDVSDAT LTALKAMLEV KQEVAPWIDL QIVAFPQEGI LSYPNGEALL EEALRLGADV
     VGAIPHFEFT REYGVESLHK TFALAQKYDR LIDVHCDEID DEQSRFVETV AALAHHEGMG
     ARVTASHTTA MHSYNGAYTS RLFRLLKMSG INFVANPLVN IHLQGRFDTY PKRRGITRVK
     EMLESGINVC FGHDDVFDPW YPLGTANMLQ VLHMGLHVCQ LMGYGQINDG LNLITHHSAR
     TLNLQDYGIA AGNSANLIIL PAENGFDALR RQVPVRYSVR GGKVIASTQP AQTTVYLEQP
     EAIDYKR
//
